Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03243734
Other study ID # 017
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 6, 2017
Est. completion date March 6, 2024

Study information

Verified date September 2023
Source US Endoscopy Group Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.


Description:

The use of cryotherapy delivered with the trūFreeze® System via noncontact spray ablates the cancer cells while allowing adjacent normal tissue to regenerate. When the liquid nitrogen is delivered to the malignant lesion the cancer cells undergo ablation induced by intracellular water being frozen in place such that ice crystals are formed. These ice crystals aggregate quickly causing immediate intracellular energy producing organelles to be destroyed leading to a non-viable cell. Subsequent tumor sloughing and absorption of apoptotic cells occurs with a subsequent debulking of the tumor mass. Normal tissue will regenerate as re-epithelialization occurs. The extreme cold of -196 degrees Celsius or a "hard freeze" leads to more extensive primary cell death over a shorter freeze time as compared to cryoprobes. A reduction of overall tumor obstruction in the esophageal lumen can reduce symptoms of dysphagia, delay the time until stent is needed, provide palliative care for patients for whom additional tri-modal therapies are not an option, and may increase quality of life in esophageal cancer patients. The studies conducted to date have provided documentation of the safety and effectiveness of spray cryotherapy (SCT) when used for malignancies in the esophagus. Measures of dysphagia relief have been described in peer reviewed literature. This study aims to provide much needed HRQOL information as well as additional tumor characteristics before and after SCT. A cohort of patients with locally persistent esophageal cancer will be studied in up to twelve (12) centers in the United States to provide important HRQOL data and more a comprehensive understanding of clinical tumor response post SCT. In the proposed study, the trūFreeze® System spray cryotherapy procedure will be performed during endoscopy. Each SCT procedure will be performed endoscopically at clinically indicated intervals of 6 weeks +/- 3 weeks. Total procedure dosimetry will be delivered at the discretion of the Investigator based on tumor location and patient tolerability. After each procedure at defined intervals, patients will be contacted and QOL symptom related information will be collected. If at any point an Investigator determines that a subject is not a candidate for further spray cryotherapy or is unable to tolerate additional procedures, they will be contacted via telephone to ascertain HRQOL information. Subject participation will last up to two years or until death


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date March 6, 2024
Est. primary completion date July 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Males and females of 18 to 89 years of age. - Subject is able to read, understand, and sign a written Informed Consent to participate in the study. - Subject has persistent esophageal cancer with local luminal involvement and who is not a surgical candidate or has completed or declined systemic therapy. - Subject is able to tolerate endoscopy Exclusion Criteria: - Subject is pregnant, nursing, or planning to get pregnant during study duration. - Subjects with an esophageal stent in situ at the time of study enrollment - Subject, as deemed by treating investigator has contraindication to endoscopy or Spray Cryotherapy Procedure. - Subject has received radiation within the past 6 weeks - Subject has received chemotherapy within the past 2 weeks Subject has received immunotherapy within 30 days - Subject has participated in another clinical study for systemic therapy within 6 weeks of baseline. - Subject has had previous Spray Cryotherapy for esophageal cancer.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
truFreeze® System spray cryotherapy
Subjects where truFreeze® System spray cryotherapy is performed

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Parkview Comprehensive Cancer Center Fort Wayne Indiana
United States Cancer Treatment Centers of America Western Regional Medical Center Goodyear Arizona
United States Spectrum Health Grand Rapids Michigan
United States Dartmouth-Hotchcock Medical Center Lebanon New Hampshire
United States North Shore-Long Island Jewish Medical Center Manhasset New York
United States University of California at Irvine Orange California
United States Virginia Commonwealth University Richmond Virginia
United States University of Rochester Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
US Endoscopy Group Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline EORTC at 14 days post cryotherapy procedure Validated Cancer Specific Quality of Life Questionnaire 14 days post spray cryotherapy
Primary Change from baseline dysphagia scale at 14 days post cryotherapy procedure Dysphagia Severity Scale 14 days post spray cryotherapy
Secondary Time to additional interventional procedure(s) other than spray cryotherapy (e.g. stent placement) baseline to procedure other than spray cryotherapy up to 2 years post SCT procedure
Secondary Overall Survival SCT to death up to 2 years post SCT procedure
Secondary Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session Describe changes in tumor up to 2 years post SCT procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT01404156 - Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Phase 2/Phase 3